222 related articles for article (PubMed ID: 16614540)
1. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis.
Hofmann C; Penner U; Dorow R; Pertz HH; Jähnichen S; Horowski R; Latté KP; Palla D; Schurad B
Clin Neuropharmacol; 2006; 29(2):80-6. PubMed ID: 16614540
[TBL] [Abstract][Full Text] [Related]
2. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
3. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Andersohn F; Garbe E
Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
[TBL] [Abstract][Full Text] [Related]
4. [Cardiac valvulopathy and dopamine agonist].
Grandas F
Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
[TBL] [Abstract][Full Text] [Related]
5. Agonism at 5-HT2B receptors is not a class effect of the ergolines.
Jähnichen S; Horowski R; Pertz HH
Eur J Pharmacol; 2005 Apr; 513(3):225-8. PubMed ID: 15862804
[TBL] [Abstract][Full Text] [Related]
6. Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells.
Oana F; Onozuka H; Tsuchioka A; Suzuki T; Tanaka N; Kaidoh K; Hoyano Y; Hiratochi M; Kikuchi S; Takehana Y; Shibata N
J Heart Valve Dis; 2014 Mar; 23(2):246-52. PubMed ID: 25076559
[TBL] [Abstract][Full Text] [Related]
7. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
8. Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.
Cavero I; Guillon JM
J Pharmacol Toxicol Methods; 2014; 69(2):150-61. PubMed ID: 24361689
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
10. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
11. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
Kekewska A; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
[TBL] [Abstract][Full Text] [Related]
12. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
13. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.
Tran T; Brophy JM; Suissa S; Renoux C
CNS Drugs; 2015 Dec; 29(12):985-98. PubMed ID: 26585874
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
[TBL] [Abstract][Full Text] [Related]
15. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Ling LH; Ahlskog JE; Munger TM; Limper AH; Oh JK
Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine use and the risk of valvular heart disease.
Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
[TBL] [Abstract][Full Text] [Related]
17. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
18. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
Ooba N; Yamaguchi T; Kubota K
Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Simonis G; Fuhrmann JT; Strasser RH
Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
[TBL] [Abstract][Full Text] [Related]
20. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
